Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.

R. C. Rock, Daniel Wan-Yui Chan, D. Bruzek, C. Waldron, J. Oesterling, Patrick Walsh

Research output: Contribution to journalArticle

Abstract

We evaluated the analytical performance of a new monoclonal immunoradiometric assay ("M-PSA") for prostate-specific antigen ("Tandem"; Hybritech Inc.) in comparison with a monoclonal immunoradiometric assay ("M-PAP") for mass measurement of prostatic acid phosphatase ("Tandem") and with a conventional enzyme-activity assay ("E-PAP") for prostatic acid phosphatase (EC 3.1.3.2). For M-PSA, the CVs were 1.3-3.0% within-run and 3.0-4.9% between-run. The minimum detectable mass concentration was 0.10 microgram/L, and linearity extended to 100 micrograms/L. The reference interval for M-PSA in 178 healthy men was 0-2.8 micrograms/L. Serum specimens from men with prostatic disease (primarily prostatic carcinoma and benign prostatic hypertrophy) were assayed by the three methods. Correlation was best between mass measurement (M-PAP) and enzyme activity (E-PAP) for prostatic acid phosphatase (r = 0.958). Results for PSA did not correlate well with those for either M-PAP (r = 0.629) or E-PAP (r = 0.387). PSA was increased in a higher percentage of specimens from men with earlier (clinical stage B) prostatic carcinoma than were results from either assay for PAP.

Original languageEnglish (US)
Pages (from-to)2257-2261
Number of pages5
JournalClinical Chemistry
Volume33
Issue number12
StatePublished - Dec 1987

Fingerprint

Immunoradiometric Assay
Prostate-Specific Antigen
Assays
Enzyme activity
Prostatic Diseases
Carcinoma
Prostatic Hyperplasia
Enzyme Assays
Enzymes
Serum
prostatic acid phosphatase

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen. / Rock, R. C.; Chan, Daniel Wan-Yui; Bruzek, D.; Waldron, C.; Oesterling, J.; Walsh, Patrick.

In: Clinical Chemistry, Vol. 33, No. 12, 12.1987, p. 2257-2261.

Research output: Contribution to journalArticle

Rock, RC, Chan, DW-Y, Bruzek, D, Waldron, C, Oesterling, J & Walsh, P 1987, 'Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.', Clinical Chemistry, vol. 33, no. 12, pp. 2257-2261.
Rock, R. C. ; Chan, Daniel Wan-Yui ; Bruzek, D. ; Waldron, C. ; Oesterling, J. ; Walsh, Patrick. / Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen. In: Clinical Chemistry. 1987 ; Vol. 33, No. 12. pp. 2257-2261.
@article{592cbf43b622489fb225fc0f25bee326,
title = "Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.",
abstract = "We evaluated the analytical performance of a new monoclonal immunoradiometric assay ({"}M-PSA{"}) for prostate-specific antigen ({"}Tandem{"}; Hybritech Inc.) in comparison with a monoclonal immunoradiometric assay ({"}M-PAP{"}) for mass measurement of prostatic acid phosphatase ({"}Tandem{"}) and with a conventional enzyme-activity assay ({"}E-PAP{"}) for prostatic acid phosphatase (EC 3.1.3.2). For M-PSA, the CVs were 1.3-3.0{\%} within-run and 3.0-4.9{\%} between-run. The minimum detectable mass concentration was 0.10 microgram/L, and linearity extended to 100 micrograms/L. The reference interval for M-PSA in 178 healthy men was 0-2.8 micrograms/L. Serum specimens from men with prostatic disease (primarily prostatic carcinoma and benign prostatic hypertrophy) were assayed by the three methods. Correlation was best between mass measurement (M-PAP) and enzyme activity (E-PAP) for prostatic acid phosphatase (r = 0.958). Results for PSA did not correlate well with those for either M-PAP (r = 0.629) or E-PAP (r = 0.387). PSA was increased in a higher percentage of specimens from men with earlier (clinical stage B) prostatic carcinoma than were results from either assay for PAP.",
author = "Rock, {R. C.} and Chan, {Daniel Wan-Yui} and D. Bruzek and C. Waldron and J. Oesterling and Patrick Walsh",
year = "1987",
month = "12",
language = "English (US)",
volume = "33",
pages = "2257--2261",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "12",

}

TY - JOUR

T1 - Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.

AU - Rock, R. C.

AU - Chan, Daniel Wan-Yui

AU - Bruzek, D.

AU - Waldron, C.

AU - Oesterling, J.

AU - Walsh, Patrick

PY - 1987/12

Y1 - 1987/12

N2 - We evaluated the analytical performance of a new monoclonal immunoradiometric assay ("M-PSA") for prostate-specific antigen ("Tandem"; Hybritech Inc.) in comparison with a monoclonal immunoradiometric assay ("M-PAP") for mass measurement of prostatic acid phosphatase ("Tandem") and with a conventional enzyme-activity assay ("E-PAP") for prostatic acid phosphatase (EC 3.1.3.2). For M-PSA, the CVs were 1.3-3.0% within-run and 3.0-4.9% between-run. The minimum detectable mass concentration was 0.10 microgram/L, and linearity extended to 100 micrograms/L. The reference interval for M-PSA in 178 healthy men was 0-2.8 micrograms/L. Serum specimens from men with prostatic disease (primarily prostatic carcinoma and benign prostatic hypertrophy) were assayed by the three methods. Correlation was best between mass measurement (M-PAP) and enzyme activity (E-PAP) for prostatic acid phosphatase (r = 0.958). Results for PSA did not correlate well with those for either M-PAP (r = 0.629) or E-PAP (r = 0.387). PSA was increased in a higher percentage of specimens from men with earlier (clinical stage B) prostatic carcinoma than were results from either assay for PAP.

AB - We evaluated the analytical performance of a new monoclonal immunoradiometric assay ("M-PSA") for prostate-specific antigen ("Tandem"; Hybritech Inc.) in comparison with a monoclonal immunoradiometric assay ("M-PAP") for mass measurement of prostatic acid phosphatase ("Tandem") and with a conventional enzyme-activity assay ("E-PAP") for prostatic acid phosphatase (EC 3.1.3.2). For M-PSA, the CVs were 1.3-3.0% within-run and 3.0-4.9% between-run. The minimum detectable mass concentration was 0.10 microgram/L, and linearity extended to 100 micrograms/L. The reference interval for M-PSA in 178 healthy men was 0-2.8 micrograms/L. Serum specimens from men with prostatic disease (primarily prostatic carcinoma and benign prostatic hypertrophy) were assayed by the three methods. Correlation was best between mass measurement (M-PAP) and enzyme activity (E-PAP) for prostatic acid phosphatase (r = 0.958). Results for PSA did not correlate well with those for either M-PAP (r = 0.629) or E-PAP (r = 0.387). PSA was increased in a higher percentage of specimens from men with earlier (clinical stage B) prostatic carcinoma than were results from either assay for PAP.

UR - http://www.scopus.com/inward/record.url?scp=0023488848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023488848&partnerID=8YFLogxK

M3 - Article

C2 - 2446807

AN - SCOPUS:0023488848

VL - 33

SP - 2257

EP - 2261

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 12

ER -